Silo Pharma (OTCQB: SILO) recently reported that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients. The psilocybin was administered “as part of a scientific research agreement (‘SRA’) entered with Silo in June 2021 to ‘determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, bipolar disorder and chronic back pain,’” a recent article reads. According to Silo Pharma CEO Eric Weisblum, the company is encouraged by the progress and looks forward to the next cohort of patients receiving therapeutic treatment and sharing the analysis of these markers when data has been analyzed and completed. “Scientific research is just beginning to recognize the potential of psychedelics to address the symptoms of numerous chronic diseases. Silo aims to catalyze the movement by fusing traditional therapeutics with psychedelic research to provide innovative treatments for fibromyalgia, post-traumatic stress disorder (‘PTSD’), chronic pain, rheumatoid arthritis, Parkinson’s, Alzheimer’s disease, and other rare neurological disorders. The company identifies and partners with leading medical universities, providing financial resources that propel cutting-edge research through the clinical stage and into commercialization.”
To view the full article, visit https://ibn.fm/fvFQq
About Silo Pharma Inc.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.